Population Pharmacokinetic Model for the Use of Intravenous or Subcutaneous Infliximab in Patients with Inflammatory Bowel Disease: Real-World Data from a Prospective Cohort Study

Background/Aims: Infliximab treatment failure in patients with inflammatory bowel disease may result from sub-optimal infliximab trough level. An understanding of pharmacokinetics (PKs) is important to maintain an optimal trough level. PK studies of the switch to subcutaneous (SC) infliximab from in...

Полное описание

Библиографические подробности

Главные авторы:	Joo Hye Song, Sung Noh Hong, Myeong Gyu Kim, Minjung Kim, Seong Kyung Kim, Eun Ran Kim, Dong Kyung Chang, Young-Ho Kim
Формат:	Artigo
Язык:	Inglês
Опубликовано:	Gastroenterology Council for Gut and Liver 2025-05-01
Серии:	Gut and Liver
Предметы:	infliximab; pharmacokinetic model; intravenous; subcutaneous; inflammatory bowel diseases
Online-ссылка:	http://gutnliver.org/journal/view.html?doi=10.5009/gnl240503
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!